Spruce Biosciences Reports First Quarter 2022 Financial Results and Provides Corporate UpdateBusiness Wire • 05/11/22
Spruce Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate UpdatesBusiness Wire • 03/14/22
Spruce Biosciences Appoints Will Charlton, M.D., M.A.S., as Chief Medical OfficerBusiness Wire • 03/14/22
Spruce Biosciences to Participate in the SVB Leerink 11th Annual Global Healthcare ConferenceBusiness Wire • 02/03/22
Spruce Biosciences Appoints Javier Szwarcberg, M.D., MPH as Chief Executive OfficerBusiness Wire • 01/05/22
Spruce Biosciences, Inc. (SPRB) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 12/14/21
Spruce Biosciences to Participate in the Piper Sandler 33rd Annual Healthcare ConferenceBusiness Wire • 11/18/21
Spruce Biosciences Reports Third Quarter 2021 Financial Results and Provides Corporate UpdatesBusiness Wire • 11/15/21
Spruce Biosciences Announces Pediatric Classic CAH Program Details During Virtual R&D DayBusiness Wire • 08/25/21
Spruce Biosciences Expands Tildacerfont Portfolio with Potential Treatment for Polycystic Ovary SyndromeBenzinga • 08/11/21
Spruce Biosciences Reports Second Quarter 2021 Financial Results and Provides Corporate UpdatesBusiness Wire • 08/10/21
Spruce Biosciences Appoints Renowned Drug Developer Kirk Ways, M.D., Ph.D. to Board of Directors.Benzinga • 06/24/21
Spruce Biosciences Appoints Renowned Drug Developer Kirk Ways, M.D., Ph.D. to Board of DirectorsBusiness Wire • 06/24/21
Spruce Biosciences Announces Publication of Phase 2 Results for Tildacerfont in Journal of Clinical Endocrinology and Metabolism.Benzinga • 06/21/21